Tibet Aim Pharm Inc
SZSE:002826
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tibet Aim Pharm Inc
Net Income (Common)
Tibet Aim Pharm Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tibet Aim Pharm Inc
SZSE:002826
|
Net Income (Common)
¥85.9m
|
CAGR 3-Years
23%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥5.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Net Income (Common)
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Net Income (Common)
-¥1.1B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tibet Aim Pharm Inc
Glance View
Tibet Aim Pharm., Inc. engages in the research and development, production, and sale of chemical drugs, and Chinese medicines. The company is headquartered in Chengdu, Sichuan and currently employs 430 full-time employees. The company went IPO on 2016-12-09. The Company’s products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Tibet Aim Pharm Inc's Net Income (Common)?
Net Income (Common)
85.9m
CNY
Based on the financial report for Sep 30, 2025, Tibet Aim Pharm Inc's Net Income (Common) amounts to 85.9m CNY.
What is Tibet Aim Pharm Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
17%
Over the last year, the Net Income (Common) growth was 158%. The average annual Net Income (Common) growth rates for Tibet Aim Pharm Inc have been 23% over the past three years , 17% over the past five years .
